MOD GRF 1-29 is a synthetic analog of the first 29 amino acids of the naturally occurring growth hormone-releasing hormone (GHRH). Researchers use it to probe how the hypothalamus stimulates growth hormone (GH) secretion from the pituitary.
Why the short peptide matters
The full GHRH molecule contains 44 residues, but early structure-activity work showed that the N-terminal 29-amino-acid segment (GRF 1-29) retains nearly full biological activity at the receptor. This insight led to the FDA-approved drug sermorelin in 1990, later withdrawn for commercial reasons rather than safety concerns.
A 1986 investigation demonstrated that the native peptide is rapidly degraded in plasma. The first two residues are cleaved by a dipeptidyl peptidase, leaving only a tiny fraction (<1/1000) of the active form. Intravenous administration produced a half‑life of roughly seven minutes, making stable analogs essential for research.
To improve stability, four amino-acid substitutions were introduced into GRF 1-29. Alanine at position 2 became D-alanine, resisting DPP-4 cleavage; asparagine at position 8 was replaced by glutamine to prevent deamination; glycine at position 15 changed to alanine, enhancing helical stability; and methionine at position 27 switched to leucine, reducing oxidation risk.
Read Also: Low-Carb Diet Best for Reversing Metabolic Syndrome
The tetrasubstituted sequence serves as the backbone for CJC-1295. The latter adds a lysine-maleimide “drug affinity complex” (DAC) that binds circulating albumin, extending its action from minutes to several days. By contrast, MOD GRF 1-29 lacks the DAC, preserving a short-acting profile while remaining more resistant to enzymatic breakdown than the native peptide.
How the analog works in the lab
Both GHRH analogs and the natural hormone engage a G-protein-coupled receptor on somatotroph cells. Activation raises intracellular cyclic AMP, which triggers protein kinase A and prompts the release of stored GH granules as well as new GH synthesis. In animal models, prolonged exposure can also stimulate somatotroph proliferation.
Endogenous somatostatin limits this pathway, so GHRH analogs generate pulsatile GH release but cannot fully override the inhibitory signal. When combined with ghrelin-receptor agonists such as GHRP-2 or ipamorelin, studies have shown synergistic GH spikes, indicating distinct mechanisms of action.
For researchers, the practical upshot is that a brief, well-timed injection of MOD GRF 1-29 can provide a clean, isolated pulse of GH without the lingering effects of albumin-bound compounds. This makes it easier to map downstream signaling events or to test how other secretagogues modify the response.
Human data on the tetrasubstituted peptide are scarce. Most published trials focus on CJC-1295 with DAC, which demonstrated 2- to 10-fold increases in GH and sustained IGF-1 elevations lasting up to 11 days after a single dose. Sermorelin and tesamorelin have richer clinical histories, the latter showing reductions in visceral fat among HIV-positive patients in a 26-week, double-blind study of 412 participants.
Read Also: Simple habits cut respiratory illness risks this season
Because peer-reviewed pharmacokinetic profiles for MOD GRF 1-29 are limited, many online sources extrapolate half-life estimates from related compounds. Users are advised to verify peptide purity through COA, HPLC chromatograms, and mass-spectrometry data before incorporating the molecule into experiments.
Despite the data gaps, the analog remains popular for its short-acting nature, enhanced stability, and compatibility with ghrelin-based secretagogues. Its design reflects a clear intent: retain the receptor-activating core while mitigating the rapid degradation that hampers the native peptide.
Practical considerations for laboratory use
When planning an experiment, confirming peptide identity is essential. Suppliers typically provide a certificate of analysis that includes high-performance liquid chromatography traces and mass-spectrometry confirmation of the exact molecular weight.
Regulatory status and research limitations
Regulatory agencies have not granted approval for MOD GRF 1-29 as a therapeutic agent. Consequently, the peptide is labeled for “research use only” and must not be administered to humans outside of a formally approved clinical trial.